Randomized Controlled Trial
Copyright ©The Author(s) 2024.
World J Clin Cases. Jun 26, 2024; 12(18): 3476-3481
Published online Jun 26, 2024. doi: 10.12998/wjcc.v12.i18.3476
Table 1 Comparison of changes in serum vasoactive intestinal peptide, motilin, and 5-hydroxytryptamine before and after treatment between the two groups (mean ± SD, pg/mL)
Indicator
Control (n = 60)
Observation (n = 60)
t value
P value
Vasoactive intestinal peptideBefore treatment41.72 ± 10.8541.80 ± 10.440.0410.967
After treatment34.64 ± 6.8027.83 ± 6.535.5950.000
MotilinBefore treatment154.71 ± 43.90158.08 ± 44.600.4170.677
After treatment198.38 ± 37.61234.82 ± 42.644.9640.000
5-hydroxytryptamineBefore treatment320.70 ± 58.91322.61 ± 60.830.1750.862
After treatment263.65 ± 52.74210.37 ± 48.275.7730.000
Table 2 Comparison of postoperative anal incontinence between the two groups (mean ± SD, score)
Indicator
Control (n = 60)
Observation (n = 60)
t value
P value
Wexner score for anal incontinenceOne month after surgery10.5 ± 1.412.0 ± 1.85.0950.000
Three months after surgery8.5 ± 0.89.8 ± 1.07.8630.000
Six months after surgery7.0 ± 1.18.6 ± 1.17.9670.000
Twelve months after surgery5.3 ± 1.36.0 ± 1.42.8380.005
Table 3 Comparison of postoperative complications between the two groups
Indicator
Control (n = 60)
Observation (n = 60)
t value
P value
ComplicationsAbdominal distension and pain42--
Incision infection31--
Anastomotic leak41--
Adhesive intestinal obstruction20--
Overall incidence13 (6.67)4 (21.67)5.5510.018